Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells

Xiaohua Li1, Ben D Chen

  • 1Department of Internal medicine and Karmanos Cancer Institute, Wayne State University School of Medicine, 550 E. Canfield, Detroit, MI 48201.

Insights

M344, a histone deacetylase inhibitor, effectively inhibits leukemia cell growth and induces apoptosis. This compound shows potential as a therapeutic strategy for leukemia patients.

Area of Science:

  • Epigenetics and Cancer Biology
  • Molecular Oncology
  • Pharmacology

Background:

  • Histone acetylation regulates gene expression in tumoregenesis.
  • Histone deacetylase (HDAC) inhibitors, like Trichostatin A, show anti-tumor potential.
  • M344 is an amide analog of Trichostatin A, investigated for its effects on leukemia.

Purpose of the Study:

  • To investigate the effects of M344 on the growth and differentiation of THP-1 human leukemia cells.
  • To determine the mechanisms by which M344 affects leukemia cell proliferation and survival.
  • To explore the therapeutic potential of M344 as an HDAC inhibitor for leukemia treatment.

Main Methods:

  • Cell culture of THP-1 human leukemia cells.
  • Treatment with varying doses of M344 (low dose < 0.2 muM, high dose 2 muM).
  • Analysis of cell cycle progression (G1 arrest), differentiation markers (c-fms), apoptosis (PARP cleavage, cytochrome c release, caspase activation), gene expression (Bax, XIAP, IL-1, TNF-alpha), and transcription factor activation (NF-kappaB).

Main Results:

  • Low-dose M344 inhibited THP-1 cell growth at G1 phase with low cytotoxicity and induced differentiation.
  • High-dose M344 induced apoptosis through intrinsic and extrinsic pathways, involving caspase activation and altered expression of apoptosis-related proteins (Bax, XIAP).
  • M344 activated NF-kappaB, transiently increased IL-1, and decreased TNF-alpha expression.

Conclusions:

  • M344 is a potent inhibitor of human leukemia cell growth and a strong inducer of apoptosis.
  • M344 demonstrates therapeutic potential for leukemia treatment through its effects on cell cycle arrest, differentiation, and apoptosis.
  • HDAC inhibitors like M344 represent promising therapeutic strategies for patients with leukemias.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...